Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor

Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20-30 Gy (24%), 30-40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4-5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1-9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2-76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.

Authors

Institutions

Publication Details

Journal
Journal of Radiation Research
Published
2024-08-20
DOI
https://doi.org/10.1093/jrr/rrae060
Citations
5
Primary Topic
Management of metastatic bone disease
Type
article
Field-Weighted Citation Impact
2.86

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor

Kayo Yoshida, Akifumi Notsu, Joichi Heianna, Norio Katoh et al.
5 citations
Journal of Radiation Research
Management of metastatic bone disease
2.86
article

Multi-institutional prospective observational study of radiotherapy for metastatic bone tumor

Kayo Yoshida, Akifumi Notsu, Joichi Heianna, Norio Katoh, Hiroki Shirato, Hisayasu Nagakura, Haruka Uezono, Takeo Takahashi, Yukinori Okada, Shigeo Takahashi, Nobue Uchida, Takafumi Komiyama, Naoyuki Shigematsu, Tetsuo Saito, Yasuo Ejima, Ayako Tonari, Isao Asakawa, Hitoshi Wada, Misako Miwa, Hiroko Ikeda, Kei Ito, Yutaro Koide, Takuya Yamazaki, Kazunari Yamada, Miho Watanabe, Hikaru Kubota, Naoto Shikama, Hideyuki Harada, Takashi Kosugi
article en
5 citations

Abstract

Purpose of this study is to evaluate patient characteristics, treatments and outcomes in bone metastasis radiotherapy practice. Patients for whom radiotherapy for bone metastasis was planned at 26 institutions in Japan between December 2020 and March 2021 were consecutively registered in this prospective, observational study. Study measures included patient characteristics, pain relief, skeletal-related events (SREs), overall survival and incidence of radiation-related adverse events. Pain was evaluated using a numerical rating scale (NRS) from 0 to 10. Irradiated dose was analyzed by the biologically effective dose (BED) assuming α/β = 10. Overall, 232 patients were registered; 224 patients and 302 lesions were fully analyzed. Eastern Cooperative Oncology Group Performance Status was 0/1/2/3/4 in 23%/38%/22%/13%/4%; 59% of patients had spinal metastases and 84% had painful lesions (NRS ≥ 2). BED was <20 Gy (in 27%), 20-30 Gy (24%), 30-40 Gy (36%) and ≥ 40 Gy (13%); 9% of patients were treated by stereotactic body radiotherapy. Grade 3 adverse events occurred in 4% and no grade 4-5 toxicity was reported. Pain relief was achieved in 52% at 2 months. BED is not related to pain relief. The cumulative incidence of SREs was 6.5% (95% confidence interval (CI) 3.1-9.9) at 6 months; no factors were significantly associated with SREs. With spinal lesions, 18% of patients were not ambulatory at baseline and 50% of evaluable patients in this group could walk at 2 months. The 6-month overall survival rate was 70.2% (95% CI 64.2-76.9%). In conclusion, we report real-world details of radiotherapy in bone metastasis.

Journal of Radiation ResearchVol. 65(5)
Chiba University (JP), St. Marianna University School of Medicine (JP), Hokkaido University (JP), NTT Medical Center (JP), Tokyo Metropolitan Komagome Hospital (JP), Juntendo University (JP), Shizuoka Cancer Center (JP), Kobe University Hospital (JP), Seirei Mikatabara General Hospital (JP), Osaka City General Hospital (JP), Suita Tokushukai Hospital (JP), Keio University Hospital (JP), University of Yamanashi Hospital (JP), Saiseikai Central Hospital (JP), Aichi Cancer Center (JP), Kagawa University Hospital (JP), Fujieda Municipal General Hospital (JP), Kyorin University Hospital (JP), Social Insurance Saitama Chuo Hospital (JP), Hyogo Prefectural Cancer Center (JP), Nagasaki University Hospital (JP), Southern Tohoku General Hospital (JP), Sendai Kousei Hospital (JP), Nara Medical University (JP), Dokkyo Medical University (JP), Saitama Medical University (JP)
AstraZeneca, Boston Scientific Corporation, Nihon Medi-Physics, Accuray, Chugai Pharmaceutical
Good health and well-being
Openalex Percentile: Top 9%
Management of metastatic bone disease
2.86
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.